IE
RAPP

Israel Englander’s Rapport Therapeutics RAPP Stock Holding History

Israel Englander’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.46M Sell
154,908
-164,644
-52% -$6.05M ﹤0.01% 2747
2026
Q1 		$10M Buy
319,552
+117,727
+58% +$3.31M ﹤0.01% 2169
2025
Q4 		$6.12M Buy
201,825
+47,651
+31% +$1.32M ﹤0.01% 2784
2025
Q3 		$4.58M Buy
+154,174
New +$2.75M ﹤0.01% 3237
2024
Q3 		– Sell
-116,782
Closed -$2.72M – 6559
2024
Q2 		$2.72M Buy
+116,782
New +$2.7M ﹤0.01% 3263

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Israel Englander's RAPP Position: Q2 2026 in Review

Israel Englander reduced its Rapport Therapeutics (RAPP) stake by 52% in Q2 2026, selling an estimated $6.05M and leaving 154,908 shares worth $6.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2747.

Israel Englander first reported a position in RAPP in Q2 2024 and has held it in 5 quarters since. The position peaked at $10M in Q1 2026. 159 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Israel Englander held 154,908 shares of Rapport Therapeutics worth $6.46M as of Q2 2026.
  • Israel Englander sold 164,644 Rapport Therapeutics shares in Q2 2026, an estimated $6.05M.
  • Rapport Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2747 holding.
  • Israel Englander first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Israel Englander's Rapport Therapeutics position peaked at $10M in Q1 2026.
  • 159 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.